Theoretical prediction of the phenoxyl radical formation capacity and cyclooxygenase inhibition relationships by phenolic compounds

Quantitative Structure-Activity Relationships

Volumn 21, Issue 6, 2002, Pages 605-612

  Ruiz, Juan ^a   Pouplana, Ramon ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Ab initio methods; Antiinflammatory; Antioxidant; COX; Critical pointZ; Free Radical Scavengers; Phenols

Indexed keywords

CARBON; HYDROGEN; PHENOL DERIVATIVE; PROSTAGLANDIN SYNTHASE;

AB INITIO CALCULATION; ARTICLE; CHEMICAL BOND; DISSOCIATION; ELECTRON; ENTHALPY; HUMAN; PREDICTION; PRIORITY JOURNAL;

EID: 0036991321     PISSN: 09318771     EISSN: None     Source Type: Journal    
DOI: 10.1002/qsar.200290003     Document Type: Article

References (35)

1. Behl, Ch., and Moosmann, B., Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach, Free Radical. Biology & Medicine, 33, 62-191 (2002).
2. Pasinetti, G.M., Cyclooxygenase and Alzheimer's disease: implications for preventive initiatives to slow the progression of clinical dementia, Arch. Geron. Gerit., 33, 13-28 (2001).
3. Schneider, C., and Brash, A. R., Stereospecificity of Hydrogen Abstraction in the Conversion of Arachidonic Acid to 15R-HETE by Aspirin-treated Cyclooxygenase-2. Implications for the alignment of substrate in the active site, J. Biol. Chem., 275, 4743-4746 (2000).
4. Asanuma, M., Nishibayashi-Asanuma, S., Miyazaki, I., Kohno, M., and Ogawa, N., Neuroprotective effects of nonsteroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals, J. Neurochem. 76, 1895-1904 (2001).
5. Rioux, N., and Castonguay, A., Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents, Carcinogenesis 19, 1394-1400 (1998).
6. Hinz, B., and Brune, K., Cyclooxygenase-2-10 Years Later, J. Pharmacol. Exp. Ther. 300, 367-375 (2002).
7. Swingle, K. F., Bell R. L., and Moore, G. G. I., Anti-inflammatory Activity of Antioxidants, in: Rainsford Ph. D. K. D., and Path, M. R. C. (Eds.) Anti-Inflammatory and antirheumatic drugs, C.R.C. Press, Florida 1989, pp. 105-126.
8. Kramer, J. B., Capiris, T., Sircar, J. C., Connor, D. T., Bornemeier, D. A., Dyer, R. D., Kuipers, P. J., Kennedy, J. A., Wright, C. D., Okonkwo, G. C., et al., Hydroxylamine analogs 2,6-di-t-butylphenols: dual inhibitors of cyclooxygenase and 5-lipoxygenase or selective 5-lipoxygenase inhibitors, Bioorg. Med. Chem. 3, 403-410 (1995).
9. Lazer, E. S., Wong, H. C, Possanza, G. J., Graham, A. G., and Farina, P. R., Antiinflammatory 2,6-Di-tert-butyl-4-(2-arylethenyl)phenols, J. Med. Chem. 32, 100-104 (1989).
10. Dewhirst, F. E., Structure-Activity Relationships for inhibition of prostaglandin cyclooxygenase by phenolic compounds, Prostaglandins 20, 209-223 (1980).
11. Mehler, E. L., and Gerhards, J., Interaction model for the antiinflammatory action of benzoic, salicylic acids and phenols, Int. J. Quantum Chem. 35, 205-214 (1989).
12. Ruiz, J., Pérez, A., and Pouplana, R., QSAR study of Phenols: relation between the phenoxyl radical formation and the antiinflammatory activity via an antioxidant mechanism, Quant. Struct.-Act. Relat. 15, 219-223 (1996).
13. Lien, E. J., Ren, S., Bui, H. H., and Wang, R., Quantitative structure-activity relationship analysis of phenolic antioxidants, Free Radical Biology & Medicine 26, 285-294 (1999).
14. Zhang, H. Y., Sun, Y. M., and Chen, D. Z., OH bond dissociation energies of phenolic compounds are determined by field/inductive effect or resonance effect? A DFT study and its implication, Quant. Struct.-Act. Relat. 20, 148-152 (2001).
15. Bader, R. F. W. and Essén, H., The characterization of atomic interactions, J. Chem. Phys. 80, 1943-1957 (1984).
16. Platts, J. A., Theoretical prediction of hydrogen bond basicity, Phys. Chem. Chem. Phys. 2, 3115-3120 (2000).
17. Platts, J. A., Theoretical prediction of hydrogen bond donor capacity, Phys. Chem. Chem. Phys. 2, 973-980 (2000).
18. BIOSYM Technologies, Inc. 10065 Barnes Canyon Road, San Diego, CA 92121.
19. Frisch, M. J., Trucks, G. W., Schlegel, H. B., Gill, P. M. W., Johnson, B. G., Robb, M. A., Cheeseman, J. R., Keith, T., Petersson, G. A., Montgomery, J. A., Raghavachari, K., Al-Laham, M. A., Zakrzewski, V. G., Ortiz, J. V., Foresman, J. B., Cioslowski, J., Stefanov, B. B., Nanayakkara, A., Challacombe, M., Peng, C. Y., Ayala, P. Y., Chen, W., Wong, M. W., Andres, J. L., Replogle, E. S., Gomperts, R., Martin, R. L., Fox, D. J., Binkley, J. S., Defrees, D. J., Baker, J., Stewart, J. P., Head-Gordon, M., Gonzalez, C., and People, J. A., GAUSSIAN 94 Rev. E.1 Gaussian Inc. Pittsburgh, P.A. 1995.
20. Biegler-Kšning, F. W., Bader, R. F. W., Tang, T. H., Calculation of the Average Properties of Atoms in Molecules (AIM), J. Comput. Chem. 3, 317-329 (1982).
21. Sanz, F., Manaut, F., Rodríguez, J., Lozoya E., and López de Briñas, E., MEPSIM: A computational package for analysis and comparison of molecular electrostatic potentials, J. Comput.-Aided Mol. Des. 7, 337-347 (1993).
22. Goodford, P. J. A., Computational Procedure for Determining Energetically Favourable Binding Sites on Biological Important Macromolecules, J. Med. Chem. 28, 849-857 (1985).
23. GRIN, GRID, GRAB and GROUP version 16.0. Molecular Discovery Ltd., 1998.
24. ClogP algorithm designed by Dr. Albert Leo programmed by Dr. David Weininger Biobyte Corp. 201 W. 4th St. Suite #204 Claremont, CA 91711, USA
25. Pouplana, R., Lozano, J. J., and Ruiz, J., Molecular modelling of the differential interaction between several non-steroidal anti-inflammatory drugs and human prostaglandin endoperoxide H synthase-2 (h-PGHS-2), J. Mol. Graph. Mod. 20, 329-343 (2002).
26. Peitsch, M. C., Protein modeling by email., Bio/Technology 13, 658 (1995).
27. Peitsch, M. C., Promod and Swiss-Model: Internet-based tools for automated comparative protein modelling, Biochem. Soc. Trans. 24, 274-279 (1996).
28. Case, D. A., Pearlman, D. A., Caldwell, J. C., Cheatham, T. E., Ross, W. S., Simmerling, C., Darden, T., Merz, K. M., Stanton, R. V., Cheng, A., Vincent, J. J., Crowley, M., Fergusson, D. M., Radmer, R., Seibel, G. L., Singh, U. C., Weiner, P., and Kollman P. A., AMBER5; University of California, San Francisco (1997).
29. García-Nieto, R., Pérez, C., and Gago, F., Automated docking and molecular dynamic simulations of nimesulide in the cyclooxygenase active site of human prostaglandin-endoperoxide synthase-2 (COX-2), J. Comput.-Aided Mol. Des. 14, 147-160 (2000).
30. Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K., and Olson, A. J., The Scripps Research Institute, La Jolla, CA, AutoDock: Automated Docking of Flexible Ligands to Receptors, Version 3.0 (1998).
31. Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K., and Olson, A. J., Automated docking using a Lamarckian genetic algorithm and a empirical binding free energy function, J. Comp. Chem. 19, 1639-1662 (1998).
32. Smith, W. A., and Marnett, L. J., Prostaglandin endoperoxide synthase: structure and catalysis, Biochim. Biophys. Acta 1083, 1-17 (1991).
33. Kurumbail, R. G., Stevens, A., Gierse, J. K., McDonald, J. J., Stegeman, R., Pak, J., Gildehaus, D., Miyashiro, J., Penning, T., Seibert, K., Isakson, P. C., and Stallings, W. C., Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents, Nature 384, 644-648 (1996).
34. Kalgutkar, A. S., Crews, B. C., Rowinson, S. W., Garner, C., Seibert, K., and Marnett, L. J., Aspirin-like molecules that covalently inactivate cyclooxygenase-2, Science 260, 1268-1270 (1998).
35. Loll, P. J., Picot, D., and. Garavito, R. M., The Structural Basis of Aspirin Activity Inferred from the Crystal-Structure of Inactivated Prostaglandin H-2 Synthase, Nature Struc. Biol. 2, 637-643 (1995).